chr17-61808634-G-A

Variant names:

Variant summary

Our verdict is Pathogenic. The variant received 14 ACMG points: 14P and 0B. PM1PP3_StrongPP5_Very_Strong

The NM_032043.3(BRIP1):c.751C>T(p.Arg251Cys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000161 in 1,613,818 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R251H) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000033 ( 0 hom., cov: 32)

Exomes 𝑓: 0.000014 ( 0 hom. )

Consequence

BRIP1
NM_032043.3 missense

Scores

Clinical Significance

Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:16U:1

Conservation

PhyloP100: 9.21

Publications

10 publications found

Variant links:

Genes affected

BRIP1 (HGNC:20473): (BRCA1 interacting helicase 1) The protein encoded by this gene is a member of the RecQ DEAH helicase family and interacts with the BRCT repeats of breast cancer, type 1 (BRCA1). The bound complex is important in the normal double-strand break repair function of breast cancer, type 1 (BRCA1). This gene may be a target of germline cancer-inducing mutations. [provided by RefSeq, Jul 2008]

BRIP1 Gene-Disease associations (from GenCC):

familial ovarian cancer
Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
Fanconi anemia
Inheritance: AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, Illumina
Fanconi anemia complementation group J
Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, ClinGen, Ambry Genetics, Labcorp Genetics (formerly Invitae)
hereditary breast carcinoma
Inheritance: AD Classification: STRONG, LIMITED, NO_KNOWN Submitted by: ClinGen, Genomics England PanelApp, Ambry Genetics, Labcorp Genetics (formerly Invitae)
colorectal adenoma
Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

BRIP1 links:

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 14 ACMG points.

PM1

In a hotspot region, there are 3 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 2 benign, 39 uncertain in NM_032043.3

PP3

MetaRNN computational evidence supports a deleterious effect, 0.981

PP5

Variant 17-61808634-G-A is Pathogenic according to our data. Variant chr17-61808634-G-A is described in ClinVar as Pathogenic/Likely_pathogenic. ClinVar VariationId is 185848.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
BRIP1	NM_032043.3 link	c.751C>T	p.Arg251Cys	missense_variant	Exon 7 of 20	ENST00000259008.7	NP_114432.2	Q9BX63-1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
BRIP1	ENST00000259008.7 link	c.751C>T	p.Arg251Cys	missense_variant	Exon 7 of 20	1	NM_032043.3	ENSP00000259008.2		Q9BX63-1

Frequencies

GnomAD3 genomes

AF:

0.0000329

AC:

AN:

152046

Hom.:

Cov.:

show subpopulations

Gnomad AFR

AF:

0.00

Gnomad AMI

AF:

0.00

Gnomad AMR

AF:

0.0000655

Gnomad ASJ

AF:

0.00

Gnomad EAS

AF:

0.00

Gnomad SAS

AF:

0.00

Gnomad FIN

AF:

0.00

Gnomad MID

AF:

0.00

Gnomad NFE

AF:

0.0000588

Gnomad OTH

AF:

0.00

GnomAD2 exomes

AF:

0.0000119

AC:

AN:

251170

AF XY:

0.00000737

show subpopulations

Gnomad AFR exome

AF:

0.0000615

Gnomad AMR exome

AF:

0.00

Gnomad ASJ exome

AF:

0.00

Gnomad EAS exome

AF:

0.00

Gnomad FIN exome

AF:

0.00

Gnomad NFE exome

AF:

0.0000176

Gnomad OTH exome

AF:

0.00

GnomAD4 exome

AF:

0.0000144

AC:

AN:

1461772

Hom.:

Cov.:

AF XY:

0.0000165

AC XY:

AN XY:

727186

show subpopulations

African (AFR)

AF:

0.000119

AC:

AN:

33480

American (AMR)

AF:

0.00

AC:

AN:

44724

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

26132

East Asian (EAS)

AF:

0.00

AC:

AN:

39694

South Asian (SAS)

AF:

0.00

AC:

AN:

86254

European-Finnish (FIN)

AF:

0.00

AC:

AN:

53416

Middle Eastern (MID)

AF:

0.00

AC:

AN:

5768

European-Non Finnish (NFE)

AF:

0.0000153

AC:

AN:

1111912

Other (OTH)

AF:

0.00

AC:

AN:

60392

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.449

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Exome Het

Variant carriers

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

GnomAD4 genome

AF:

0.0000329

AC:

AN:

152046

Hom.:

Cov.:

AF XY:

0.0000135

AC XY:

AN XY:

74276

show subpopulations

African (AFR)

AF:

0.00

AC:

AN:

41376

American (AMR)

AF:

0.0000655

AC:

AN:

15268

Ashkenazi Jewish (ASJ)

AF:

0.00

AC:

AN:

3468

East Asian (EAS)

AF:

0.00

AC:

AN:

5182

South Asian (SAS)

AF:

0.00

AC:

AN:

4826

European-Finnish (FIN)

AF:

0.00

AC:

AN:

10592

Middle Eastern (MID)

AF:

0.00

AC:

AN:

316

European-Non Finnish (NFE)

AF:

0.0000588

AC:

AN:

68014

Other (OTH)

AF:

0.00

AC:

AN:

2092

Allele Balance Distribution

Red line indicates average allele balance

Average allele balance: 0.535

Heterozygous variant carriers

0.00

0.20

0.40

0.60

0.80

0.95

Allele balance

Age Distribution

Genome Het

Variant carriers

<30

30-35

35-40

40-45

45-50

50-55

55-60

60-65

65-70

70-75

75-80

>80

Age

Alfa

AF:

0.0000195

Hom.:

Bravo

AF:

0.0000491

ExAC

AF:

0.00000824

AC:

EpiCase

AF:

0.000164

EpiControl

AF:

0.0000593

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:16Uncertain:1

Revision: criteria provided, multiple submitters, no conflicts

LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome

Pathogenic:5

Feb 22, 2023

Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Dec 07, 2022

Ambry Genetics

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

The p.R251C pathogenic mutation (also known as c.751C>T), located in coding exon 6 of the BRIP1 gene, results from a C to T substitution at nucleotide position 751. The arginine at codon 251 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration was reported in one individual diagnosed with Fanconi anemia along with a second alteration in BRIP1 (Chandrasekharappa SC et al. Blood 2013 May;121(22):e138-48). This alteration was also identified the homozygous state in a cohort of Israeli patients diagnosed with Fanconi anemia (Steinberg-Shemer O et al. Haematologica. 2019 Sep), as well as in 55-year-old identical twins, both affected with cancer and a late-onset and less severe form of Fanconi anemia, leading the authors to speculate that this may be a hypomorphic allele (Stevens H et al. Am. J. Hematol. 2016 Dec;91:1273-1276). This alteration has been reported in 0/7636 unselected prostate cancer patients and 1/12,366 male controls of Japanese ancestry (Momozawa Y et al. J. Natl. Cancer Inst. 2019 Jun). Functional studies showed this alteration to be deficient in helicase activity, as well as DNA and ATP binding. In addition, cells expressing this alteration showed increased cell death in response to DNA damaging agents compared to wild type (Guo M et al. J. Biol. Chem. 2014 Apr;289:10551-65). Structural analysis indicates that p.R251C likely disrupts ligand binding in a functionally significant and sensitive region (Ambry internal data, He Y et al. EMBO Rep. 2010 Mar;11:180-6; He Y et al. Nature. 2016 05;533:359-65). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Oct 15, 2024

Color Diagnostics, LLC DBA Color Health

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This missense variant replaces arginine with cysteine at codon 251 in the helicase domain of the BRIP1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function. Functional studies have shown that the mutant protein shows no DNA helicase activity, reduced ATP binding activity, reduced DNA-dependent ATPase activity, and failed to complement BRIP1-null cell line (PMID: 24573678, 27107905). This variant has been reported in two homozygous individuals affected with Fanconi anemia (PMID: 27427815, 31558676), as well as in an individual affected with Fanconi anemia in compound heterozygous state with a deleterious p.His396Asp variant (PMID: 23613520) (ClinVar variation ID: 659729). In a large breast cancer case-control study, this variant has been observed in 3/60463 cases and 2/53459 controls (PMID: 33471991 - Leiden Open Variation Database DB-ID BRIP1_000010). This variant has also been reported in 2 unaffected control individuals in pancreatic and prostate cancer case-control studies and absent in affected individuals (PMID: 31214711, 32980694). This variant has been identified in 3/251170 chromosomes in the general population by the Genome Aggregation Database (gnomAD). In summary, this variant has been shown to impair BRIP1 protein function. The observation of this variant in biallelic individuals affected with autosomal recessive Fanconi anemia indicates that this variant contributes to disease. Based on the available evidence, this variant is classified as Likely Pathogenic. -

Jul 02, 2024

Hereditary Cancer Laboratory, Hospital Universitario 12 de Octubre

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

PS3+PM2+PP3+PP5 -

Oct 18, 2021

Sema4, Sema4

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:curation

- -

Familial cancer of breast

Pathogenic:3

Oct 10, 2023

Baylor Genetics

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Feb 13, 2024

Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

PS3, PM1, PM2, PP3 -

Feb 28, 2023

Myriad Genetics, Inc.

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 24573678]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 23613520, 31586946]. -

Fanconi anemia complementation group J

Pathogenic:2

Apr 19, 2019

Revvity Omics, Revvity

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Apr 29, 2022

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance:Pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Variant summary: BRIP1 c.751C>T (p.Arg251Cys) results in a non-conservative amino acid change located in the Helicase-like, DEXD box c2 type domain of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.2e-05 in 251170 control chromosomes. c.751C>T has been reported in the literature in multiple individuals affected with Fanconi Anemia Complementation Group J in the homozygous and compound heterozygous state (Chandrasekharappa_2013, Stevens_2016, Steinberg-Shermer_2020, Bogliolo_2020) as well as in patients with breast cancer in the heterozygous state (e.g. Schrader_2016). These data indicate that the variant is very likely to be associated with disease. In functional studies, the variant was shown to abolish DNA helicase activity and DNAprotein displacement activity (Guo_2014). Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Five submitters classified the variant as likely pathogenic/pathogenic while one classified the variant as VUS. Based on the evidence outlined above, the variant was classified as pathogenic. -

not provided

Pathogenic:2

Sep 16, 2022

Quest Diagnostics Nichols Institute San Juan Capistrano

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

The frequency of this variant in the general population, 0.000012 (3/251170 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, this variant has been reported in individuals with breast cancer (PMID: 26921362 (2016), 26556299 (2016)), Fanconi anemia (PMID: 31586946 (2020), 31558676 (2020), 27427815 (2016), 23613520 (2013)), and pancreatic cancer (PMID: 31214711 (2020)). In a large breast cancer association study, this variant was reported in individuals affected with breast cancer and in healthy controls (PMID: 33471991 (2021), https://databases.lovd.nl/shared/variants/BRIP1). Functional studies reported this variant to be damaging to cell survival, DNA helicase activity, DNA binding, ATP hydrolysis activity and binding, as well as DNA repair functions (PMID: 27107905 (2016), 24573678 (2014)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as likely pathogenic. -

Jun 06, 2023

GeneDx

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

Observed in the homozygous and compound heterozygous state in individuals with Fanconi anemia referred for genetic testing at GeneDx and in the published literature (Chandrasekharappa et al., 2013; Stevens et al., 2016; Bogliolo et al., 2020); Observed in individuals with breast cancer (Easton et al., 2016; Schrader et al., 2016); Published functional studies demonstrate a damaging effect: deficient in vitro complementation in a BRIP1 null cell line and reduced DNA binding (Guo et al., 2014); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 25374583, 31586946, 33028645, 23613520, 28235761, 27107905, 26596371, 26921362, 26556299, 27427815, 33137625, 31558676, 31214711, 24573678, 19763819, 22692731, 11301010, 33471991) -

Familial cancer of breast;C1836860:Fanconi anemia complementation group J

Pathogenic:1

Jan 30, 2025

Labcorp Genetics (formerly Invitae), Labcorp

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 251 of the BRIP1 protein (p.Arg251Cys). This variant is present in population databases (rs752309409, gnomAD 0.0009%). This missense change has been observed in individuals with breast cancer and/or Fanconi anemia (PMID: 23613520, 26556299, 27427815, 31558676, 31586946). ClinVar contains an entry for this variant (Variation ID: 185848). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on BRIP1 protein function. Experimental studies have shown that this missense change affects BRIP1 function (PMID: 24573678, 27107905). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -

BRIP1-related disorder

Pathogenic:1

May 09, 2024

PreventionGenetics, part of Exact Sciences

Significance:Likely pathogenic

Review Status:no assertion criteria provided

Collection Method:clinical testing

The BRIP1 c.751C>T variant is predicted to result in the amino acid substitution p.Arg251Cys. This variant was observed in an individual with early-onset breast cancer (Schrader et al. 2016. PubMed ID: 26556299, eTable S5 & S7). This variant has also been reported in trans with another missense variant and in the homozygous state in individuals with Fanconi anemia (Chandrasekharappa et al. 2013. PubMed ID: 23613520; Stevens et al. 2016. PubMed ID: 27427815; Bogliolo et al. 2019. PubMed ID: 31586946; Steinberg-Shemer et al. 2019. PubMed ID: 31558676). Functional in vitro assays showed that this variant leads to abolished DNA helicase activity and impairs DNA binding (Guo et al. 2016. PubMed ID: 27107905). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD and is reported as pathogenic/likely pathogenic by the majority of entries in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/185848/). This variant is interpreted as likely pathogenic. -

Familial ovarian cancer

Pathogenic:1

Jul 25, 2023

Department of Pathology and Laboratory Medicine, Sinai Health System

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Hereditary breast ovarian cancer syndrome

Pathogenic:1

Apr 19, 2022

National Health Laboratory Service, Universitas Academic Hospital and University of the Free State

Significance:Likely pathogenic

Review Status:criteria provided, single submitter

Collection Method:clinical testing

- -

Ovarian cancer;C1836860:Fanconi anemia complementation group J

Uncertain:1

Oct 10, 2017

Counsyl

Significance:Uncertain significance

Review Status:no assertion criteria provided

Collection Method:clinical testing

This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Pathogenic

0.95

BayesDel_addAF

Pathogenic

0.49

BayesDel_noAF

Pathogenic

0.47

CADD

Pathogenic

(source)

DANN

Pathogenic

1.0

DEOGEN2

Pathogenic

0.80

D;.

Eigen

Pathogenic

1.0

Eigen_PC

Pathogenic

0.94

FATHMM_MKL

Pathogenic

0.99

LIST_S2

Pathogenic

0.98

D;D

M_CAP

Pathogenic

0.72

MetaRNN

Pathogenic

0.98

D;D

MetaSVM

Pathogenic

1.0

MutationAssessor

Pathogenic

4.5

H;H

PhyloP100

9.2

PrimateAI

Uncertain

0.78

PROVEAN

Pathogenic

-7.5

D;.

REVEL

Pathogenic

0.95

Sift

Pathogenic

0.0

D;.

Sift4G

Pathogenic

0.0

D;D

Polyphen

1.0

D;.

Vest4

0.94

MutPred

0.86

Loss of MoRF binding (P = 0.0047);Loss of MoRF binding (P = 0.0047);

MVP

1.0

MPC

0.80

ClinPred

1.0

GERP RS

5.3

RBP_binding_hub_radar

0.0

RBP_regulation_power_radar

1.7

Varity_R

0.95

gMVP

0.93

Mutation Taster

=2/98

disease causing (ClinVar)

(source)

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.0

Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

Publications

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

Age Distribution

Age Distribution

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

Other links and lift over